Autoantibody Profiles Of Myasthenia Gravis, Thymoma, and Lambert-Eaton Myasthenic Syndrome

Serum AChR Modulating Antibody Values and Interpretation

May 2012

Results from the modulating assay should be interpreted as follows: for non-myasthenia gravis patients this would be 0% to 20% loss, myasthenia gravis patients >30% loss, that is generally proportional to clinical severity, patients with myasthenia gravis and thymoma have >90% loss, patients with Lambert-Eaton syndrome can have >30% loss in 5% to 10% of patients.

< Previous Slide

Serum Antibody Values and Interpretation

Next Slide >

 

Jump to section:

• Introduction
• Serological Diagnostic Algorithms
• 'Hot Topic' Points
• What are MG and LES?
• What are MG and LES?
• MG: Clinical Diagnosis
• MG: Neoplastic Accompaniments
• LES: Clinical Diagnosis
• LES: Electromyography (EMG) Findings
• LES: Neoplastic Accompaniments
• Autoantibodies Aiding MG Diagnosis
• Autoantibodies Aiding MG Diagnosis
• Single Assay Detects AChR Modulating and AChR Blocking Antibody
• Serum AChR Modulating Antibody Values and Interpretation
• Reasons to Discontinue Testing for AChR Blocking Antibody
• Striational Antibodies
• Autoantibodies Detected in MG Patients With Thymoma
• Autoantibodies Aiding the Diagnosis of LES
• Autoantibodies Aiding the Diagnosis of LES
• MGEA/83370 Myasthenia Gravis (MG) Evaluation, Adult Algorithm
• MGEP/83371 Myasthenia Gravis (MG) Evaluation, Pediatric Algorithm
• MGETH/83372 Myasthenia Gravis (MG) Evaluation, Thymoma Algorithm
• MGLES/83369 Myasthenia Gravis (MG)/Lambert-Eaton Syndrome (LES) Algorithm
• Summary
• Questions?